Skip to content

CorMedix CRMD Q4 2024 Annual earnings

Reported March 25, 2025 · Before market open

Revenue estimate$31.3M
EPS estimate$0.17

Next report

Aug 6, 2026 (In 3 weeks)
Revenue estimate$96.0M
EPS estimate$0.26

Financials

Q4 2024

Income statement

See full
Revenue$31.2M
Gross profit$30.1M

Balance sheet

See full
Cash & equivalents$40.8M-7.0%
Total debt$517.0K-22.6%
Total equity$84.7M+20.7%
Total assets$118.8M+44.8%

Cash flow

See full
Operating cash flow-$5.6M+47.7%
CapEx$10.1K-96.6%
Free cash flow-$5.6M+49.1%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$491.49M+138%
Enterprise value$451.25M+177%
P/S11.3×

Profitability

See full
Gross margin92.9%
FCF margin-116.7%

Returns & leverage

See full
Debt / equity0.0×
Current ratio3.4×-3.6×

Segments

By product

See full
DefenCath$10.9M

Versus estimates

Ask the moment CorMedix reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did CorMedix report Q4 2024 earnings?
CorMedix (CRMD) reported Q4 2024 earnings on March 25, 2025 before market open.
What were CorMedix's Q4 2024 revenue and EPS?
CorMedix reported revenue of $31.2M and diluted EPS of $0.22 for Q4 2024.
Did CorMedix beat estimates in Q4 2024?
Revenue missed the consensus estimate of $31.3M by $58.1K. EPS beat the consensus estimate of $0.17 by $0.05.
Where can I find CorMedix's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001013762-25-001852) directly on SEC EDGAR. The filing index links above go to sec.gov.